Literature DB >> 8514682

Indomethacin compromises hemodynamics during positive-pressure ventilation, independently of prostanoids.

D D Malcolm1, J L Segar, J E Robillard, S Chemtob.   

Abstract

We examined whether prostanoids contribute to the impaired cardiac function and decrease in regional blood flow induced by increasing mean airway pressure. Using microspheres, we measured cardiac output and major organ blood flow and assayed prostaglandin E2, 6-ketoprostaglandin F1 alpha, and thromboxane B2 in blood at mean airway pressures of 5-25 cmH2O in mechanically ventilated newborn piglets treated with ibuprofen (40 mg/kg, n = 6), indomethacin (0.3 mg/kg, n = 6), or vehicle (n = 6). Blood gases and pH were stable throughout the experiments. Prostanoid levels remained constant with increasing mean airway pressure in vehicle-treated pigs and were unchanged by indomethacin. However, ibuprofen decreased the prostanoid levels at all mean airway pressures studied (P < 0.01). As ventilatory pressure was progressively increased, cardiac output decreased gradually and similarly by 42-45% (P < 0.05) in all groups. At the highest mean airway pressure, blood flow decreased to the kidneys by 37-57%, to the ileum by 58-74%, and to the colon by 53-71% (P < 0.05) in all groups. Cerebral blood flow remained constant at all ventilatory pressures regardless of the treatment. There was no difference in cardiac output and regional hemodynamics between ibuprofen- and vehicle-treated animals. However, after indomethacin, ileal blood flow at the higher ventilatory pressures was 41-46% lower and cerebral blood flow at all mean airway pressures was 14-25% lower than after the other treatments (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514682     DOI: 10.1152/jappl.1993.74.4.1672

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  10 in total

1.  Treatment of patent ductus arteriosus with ibuprofen.

Authors:  B Van Overmeire; I Follens; S Hartmann; W L Creten; K J Van Acker
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

2.  Pharmacoeconomics of Surgical Interventions vs. Cyclooxygenase Inhibitors for the Treatment of Patent Ductus Arteriosus.

Authors:  Charles J Turck; Wallace Marsh; James G Stevenson; John M York; Henry Miller; Snehal Patel
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

3.  Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors:  Karen E Corff; Kris C Sekar
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

4.  Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine.

Authors:  Edmund V Capparelli
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 5.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

Review 6.  NSAID-induced nephrotoxicity from the fetus to the child.

Authors:  L Cuzzolin; M Dal Cerè; V Fanos
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

Review 7.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

8.  Effect of oral ibuprofen on patent ductus arteriosus in premature newborns.

Authors:  Sabry Ghanem; Mansour Mostafa; Mohamed Shafee
Journal:  J Saudi Heart Assoc       Date:  2010-03-10

Review 9.  Nonsteroidal anti-inflammatory agents in neonates.

Authors:  John L Morris; David A Rosen; Kathleen R Rosen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).

Authors:  Tim Hundscheid; Wes Onland; Bart van Overmeire; Peter Dijk; Anton H L C van Kaam; Koen P Dijkman; Elisabeth M W Kooi; Eduardo Villamor; André A Kroon; Remco Visser; Daniel C Vijlbrief; Susanne M de Tollenaer; Filip Cools; David van Laere; Anne-Britt Johansson; Catheline Hocq; Alexandra Zecic; Eddy Adang; Rogier Donders; Willem de Vries; Arno F J van Heijst; Willem P de Boode
Journal:  BMC Pediatr       Date:  2018-08-04       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.